Navigation Links
Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced it has re-scheduled its presentation at the Credit Suisse 2011 Healthcare Conference in Phoenix to Thursday, November 10, 2011 at 3:00 p.m. MT/5:00 p.m. ET/2:00 p.m. PT. Previously, the presentation had been scheduled for Wednesday, November 9, 2011 at 11:30 a.m. MT/1:30 p.m. ET/10:30 a.m. PT. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
2. Amylin Pharmaceuticals to Present at the Credit Suisse 2011 Healthcare Conference
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
7. Amylin Pharmaceuticals to Webcast Second Quarter Results
8. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
9. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
10. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
11. Lilly Comments on Court Ruling in Amylin Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... New York, NY (PRWEB) , ... May 26, ... ... cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon ... Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & ... over 20 years of experience in leading technology and human resources operations for ... university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , ...
Breaking Medicine News(10 mins):